TACE Plus Lenvatinib Versus TACE Plus Sorafenib for Unresectable Hepatocellular Carcinoma With Portal Vein Tumor Thrombus: A Prospective Cohort Study

Overview of attention for article published in Frontiers in oncology, December 2021

Altmetric Badge

Mentioned by

twitter: 1 X user

Citations

dimensions_citation: 35 Dimensions

Readers on

mendeley: 14 Mendeley

Summary X Dimensions citations

So far, Dimensions has found 35 publications that cite this research output.

35

The most recent citing publications are shown below. View all 35 publications that cite this research output on Dimensions.

CRAFITY score benefits hepatocellular carcinoma patients treated with transarterial chemoembolization and lenvatinib

Article in Cancer Medicine (June 2024)

Lenvatinib in combination with transarterial chemoembolization vs. sorafenib in combination with transarterial chemoembolization for unresectable hepatocellular carcinoma: A network meta‑analysis

Article in Oncology Letters (June 2024)

Hepatic artery infusion chemotherapy combined with camrelizumab plus rivoceranib for hepatocellular carcinoma with portal vein tumor thrombosis: a multicenter propensity score-matching analysis

Article in Hepatology International (May 2024)

This page shows the most recent citations of this research output.

Click here to find out how to access more activity.